title: [Treatment of recurrent pulmonary tuberculosis].
abstract: BACKGROUND
  Tuberculosis (TB) is a greatest public health problem of the world. This work aims to study the antituberculous treatment and the evolution of the patients with recurrent tuberculosis.
  
  
  METHODS
  The study is a retrospective study on 64 patients with recidivant pulmonary TB: A1 group: at the first TB attack; A2 group: at the time of recidivant TB, and 105 controls patients with confirmed TB without recidive.
  
  
  RESULTS
  Multidrug-resistant TB is more frequent with recidivant TB (21.1% vs 3%, P<0.05) and also extensively drug-resistant. Antituberculous treatment duration in group A1, A2 and T was respectively 8.63 months, 9.79 months, and 7.08 months. Antituberculous drug complications were more frequent in group A2 compared to group T (76.1% vs 41.2%; P<0.001).
  
  
  CONCLUSIONS
  All tuberculous patients, specially recidivant TB, should benefit of particular care and drug protocol adaptation.
authors.affiliation: Service de pneumologie-allergologie, pavillon-II, hôpital Abderrahmen-Mami, route de Bizerte, Ariana, Tunisia. jihenbenamar@gmail.com
authors.forename: J
authors.initials: J
authors.lastname: Ben Amar
authors.forename: H
authors.initials: H
authors.lastname: Racil
authors.forename: M
authors.initials: M
authors.lastname: Mami
authors.forename: S
authors.initials: S
authors.lastname: Cheikh Rouhou
authors.forename: M
authors.initials: M
authors.lastname: Zarrouk
authors.forename: A
authors.initials: A
authors.lastname: Chabbou
mesh_terms: D000328:Adult; D000995:Antitubercular Agents / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D012008:Recurrence; D012189:Retrospective Studies; D018088:Tuberculosis, Multidrug-Resistant / Q000188:drug therapy*; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy*
chemical_list: D000995:Antitubercular Agents